[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mesenchymal-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mesenchymal-tumor":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":5},"100658550","ultra-rapid-profiling-and-drug-screening-for-treatment-selection-in-patients-with-relapsed-or-recurrent-rare-brain-tumors-100658550",false,"NCT07851636","Ultra-Rapid Profiling and Drug Screening for Treatment Selection in Patients With Relapsed or Recurrent Rare Brain Tumors","A Pilot Trial of Screening and Ultra-Rapid Profiling to Enable Real-Time Neuro-Oncology Validation and Actionable Treatment Selection for Patients With Relapsed or Recurrent Rare Brain Tumors","SUPERNOVA-RBT","Inclusion Criteria:\n\n1. Patients must have a relapse or recurrence of one of the following rare brain tumors:\n\n   * CNS sarcoma (e.g. EWS, CIC, DICER1 altered)\n   * BCOR altered tumors (e.g. BCOR ITD; BCOR, BCORL1, EP300, fused)\n   * Mesenchymal tumors (e.g. FET::CREB altered tumors)\n   * MN1::PATZ1 fused tumors\n   * PLAG- altered tumors\n   * Astroblastomas\u002FMN-1 altered (e.g. EWSR2BEND2 altered)\n   * Unclassifiable tumors\n   * Other rare brain tumors: (e.g. recently described, poorly characterized, and\u002For ambiguous entities)\n2. Participant must be a candidate for surgical resection or biopsy.\n\n   • Participants must have surgically accessible disease.\n3. Prior therapy\n\n   • The participant must have a relapsed or recurrent rare brain tumor following at least one prior therapy for initial diagnosis or previous recurrence prior to study registration:\n   * Surgery followed by observation.\n   * Multi-modality therapy: surgery, radiation, and\u002For chemotherapy\n4. Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.\n\n   * Biologic agent: Participant must have recovered from any toxicity potentially related to the agent.\n   * Last radiation at least 7 days prior to therapy start\n5. Karnofsky 50 for participants \\> 16 years of age and Lansky 50 for participants \\\u003C16 years of age\n6. Corticosteroids: Subjects who are receiving dexamethasone or equivalent must be on a stable or decreasing dose for at least 1 week prior to therapy start.\n7. The effects of the agents used in this study on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 4 months after completion of therapy administration.\n8. Adequate neurologic function defined as:\n\n   • Participants with seizure disorders may be enrolled if seizures are well controlled. Participants on non-enzyme inducing anticonvulsants may be excluded pending interaction(s) with study drug.\n9. A legal parent or guardian must be able to understand and agree to sign a written informed consent and assent document, as appropriate.\n\nExclusion Criteria:\n\n1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection.\n2. Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required prior to start of therapy.","ALL","45 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in of performing real-time drug screening on tissue taken during surgery in patients with relapsed ultra rare brain tumors (BCOR -altered, MN1-altered, CNS Sarcomas, other rare brain tumors) and of having a specialized tumor board assign a treatment plan based on the results of the drug screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed ultra rare brain tumors to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.",[27,28,29,30,31,32],"Rare CNS Tumor","FOXR2-activated","BCOR ITD Sarcoma","CNS Sarcoma","PLAG-altered Tumors","Mesenchymal Tumor",[34,30,35,36,37,38,39,40,41,42],"Brain Tumor","BCOR altered tumor","Mesenchymal tumor","MN1 fused tumor","PATZ1 fused tumor","MN1 altered tumor","Astroblastoma","Drug Screening","Personalized Treatment","RECRUITING","2026-10-12",{"date":46,"type":47},"2026-10-13","ACTUAL",{"date":49,"type":21},"2026-10",{"date":51,"type":21},"2032-10",{"name":53,"class":54},"Adriana Fonseca","OTHER"]